drugset / Trial / NCT05692050

Expanded Access to Epcoritamab

NCT05692050

Expanded access No longer available AbbVie Genmab · collab

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Epcoritamab Monoclonal antibody Subcutaneous

Indications